Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
Table of Contents

The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:
  •      the rate of progress and cost of our clinical trials and other product development programs for Contrave, Empatic and any other product candidates that we may develop, in-license or acquire;
  •      the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our product candidates;
  •      the costs and timing of completion of outsourced commercial manufacturing supply arrangements for each product candidate;
  •      the timing of regulatory approval of our product candidates, if at all;
  •      the costs of establishing sales, marketing and distribution capabilities, should we elect to do so;
  •      the effect of competing technological and market developments; and
  •      the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish.
Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies. We currently have no commitments or agreements relating to any of these types of transactions.
Until we can generate a sufficient amount of product revenue and achieve profitability, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our development programs or our commercialization efforts.
Our quarterly operating results may fluctuate significantly.
We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:
  •      variations in the level of expenses related to our two existing product candidates or future development programs;
  •      addition or termination of clinical trials or funding support;
  •      any intellectual property infringement lawsuit in which we may become involved;
  •      regulatory developments affecting our product candidates or those of our competitors;
  •      our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and
  •      if either of our product candidates receives regulatory approval, the level of underlying demand for our product candidates and wholesalers’ buying patterns.
If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.